Journal of Clinical Oncology
Articles in this Issue
Enhancing outcomes in mCRPC: The impact of androgen receptor inhibitor sequencing before ¹⁷⁷Lu-PSMA-617 therapy.
e17068 Background: Prostate-specific membrane antigen (PSMA) is a key therapeutic target in metastatic castration-resistant prostate cancer (mCRPC). Eleva...
Incident reporting and outcomes of gastrointestinal adverse events with immune checkpoint inhibitors.
e14663 Background: Immune checkpoint inhibitor therapies act by blocking inhibitory molecules involved in the regulation of T cells, thus releasing tumor-...
Survival disparities in cervical cancer patients with and without HIV at Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH).
e17539 Background: Cervical cancer is the leading cause of cancer-related deaths among Kenyan women, with 3,211 deaths reported in 2023. Women with HIV ha...
Outcomes of neoadjuvant therapy in advanced melanoma: A systematic review and meta-analysis.
e21543 Background: Neoadjuvant therapy has emerged as a promising approach in the management of melanoma, offering potential advantages over traditional a...
Survival impact of lymphocytopenia during chemoradiation in locally advanced NSCLC patients treated with adjuvant durvalumab.
8054 Background: Adjuvant durvalumab has transformed the treatment landscape for patients with locally advanced non-small cell lung cancer (NSCLC) followi...
Clinical significance of germline CFTR mutations in pancreatic cancer.
10591 Background: Pancreatic ductal adenocarcinoma (PDAC) remains a malignancy with high cancer-related mortality. The majority of PDAC is sporadic, but a...
<i>BRAF</i> -V600E papillary thyroid cancer: Updated analysis of real-world patient data.
6099 Background: Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, usually characterized by a good prognosis after surgery with or...
Racial disparities in tenosynovial giant cell tumor: An analysis of the Surveillance, Epidemiology and End Results database.
e23517 Background: Tenosynovial Giant Cell tumor (TGCT) is a rare disease classified either as localized (L-TGCT) or as diffuse type (D-TGCT). Epidemiolog...
Treating the untended: Real-world insights into enfortumab vedotin plus pembrolizumab for frail metastatic urothelial carcinoma patients excluded or underrepresented in clinical trials (GUARDIANS).
e16548 Background: Patients with terminal renal failure (GFR <30 ml/min or dialysis), poor performance status (ECOG ≥2), and/or age ≥80 are often exclu...
Advanced ensemble stacking model employing cfDNA fragmentation for early detection of esophageal and gastric cancer.
e16112 Background: Esophageal and gastric cancers are often detected at late stages due to asymptomatic early stages and limitations of current diagnostic...
Prevalence of breast cancer across racial, socioeconomic, and regional groups in the US: Analysis of comorbidity distributions using the National Inpatient Sample Database in 2019-2020.
e13161 Background: Despite advancements in breast cancer screening, it remains the most common cancer among women after skin cancer and the second leading...
Cost-effectiveness of NTRK testing strategies for detecting NTRK fusions in solid tumors in China.
3131 Background: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in many solid tumors. With the inclusion of the targeted...
Updated results from phase 2b study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma (MM) relapsing on current therapy.
7554 Background: Selinexor is a potent selective inhibitor of nuclear export and exhibits synergistic effects when combined with other myeloma therapies....
Identifying multi-level social determinants for disparities in survival and patient-reported outcomes in national head and neck cancer trials.
11066 Background: This study aimed to determine to what extent area-level social determinants of health (SDOH) interact with individual, institutional, an...
Analysis of trends in race and gender disparities in incidence-based mortality in patients diagnosed with soft tissue sarcomas from 2000 to 2021.
e23553 Background: The incidence of soft tissue sarcomas has been observed to be higher in males compared to females and more in African Americans compare...
Overall survival in patients with HR+/HER2- advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus an aromatase inhibitor: A US Food and Drug Administration pooled analysis.
1055 Background: Cyclin-dependent kinase 4/6 inhibitors (CDKI) are FDA-approved for use in combination with aromatase inhibitors (AI) for the treatment of...
Systemic therapies for advanced melanoma after immunotherapy failure: Efficacy and safety insights.
e21552 Background: Immune checkpoint inhibitors (ICIs) and targeted therapies have significantly improved clinical outcomes in advanced melanoma. However,...
Dissecting survival disparities in Philadelphia chromosome–positive vs. negative B-cell acute lymphoblastic leukemia: A decade-long Surveillance, Epidemiology, and End Results (SEER) data-based investigation (2010–2021).
e18521 Background: Philadelphia chromosome (Ph) status is a critical prognostic marker in B-cell acute lymphoblastic leukemia (B-ALL). This study evaluate...
Intersectional disparities in mortality of laryngeal cancer: A retrospective analysis.
e22538 Background: Laryngeal cancer accounts for around 1% of cancer cases and deaths. Early detection improves prognosis, with a 5-year survival rate of...
Patient transit and radiotherapy: Cost-effectiveness approach to environmental health savings.
e23146 Background: Environmental pollution and climate change exacerbate risks for cancer patients, potentiating carcinogenesis, respiratory illness, and...
QuANTUM-Wild: A phase 3, randomized, double-blind, placebo-controlled trial of quizartinib in combination with chemotherapy and as single-agent maintenance in <i>FLT3</i> -ITD–negative acute myeloid leukemia (AML).
TPS6580 Background: Quizartinib (Quiz) is an oral, selective, type-II FLT3 inhibitor with potent activity against wild-type (wt) FLT3, FLT3-ITDs, and othe...
Use of local estrogen therapy among breast cancer patients in SEER-MHOS database.
578 Background: Anti-hormonal therapy with tamoxifen or aromatase inhibitors is a key component in the treatment of hormone receptor-positive breast cance...
Disaggregating Asian American and Pacific Islander subgroups to evaluate disparities in breast cancer characteristics and outcomes.
1595 Background: When Asian American and Pacific Islander (AAPI) subgroups are aggregated under the labels “AAPI” or “Asian,” subgroup‐specific difference...
Advancing the science of cancer in Latinos.
e13808 Background: Cancer is a leading cause of death for Latinos. They experience higher rates than their white peers of preventable, infectious-agent-ca...
Efficacy of second line (2L) treatment with tivozanib (Tivo) as monotherapy or with nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (Ipi)/Nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the phase 3 TiNivo-2 study.
4540 Background: In TiNivo-2, the addition of Nivo to Tivo did not prolong progression-free survival (PFS) relative to Tivo alone (Choueiri, Lancet 2024)....